Company Overview and News
This is the third month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $891.57.
GIS O.PRF WBA ENB OPRF JCI HSY ABBV MMM POL MO SMG IRET.PR DUKH GD IRET.PRC TRV IRET.PRB GPT.PRB MAIN BX CMI ENB RY BNS JNJ TROW GPT VZ ABBV MSFT WPC ADM PFE CLX PM PFBC SKT SCL CTL IRET OXLCM OXLCO TD ETN OXLCN BNS CM MSCA GPT.PRA INTC TD IBM IRET.PRCL RY TNTTF LYB O MSB DUK SNX OXLC IRM MSCA.CL EMRAF ORI PPL BMRC DLR CBL
Part 2 of this article discusses two topics/trends impacting PSEC’s future dividend and NAV sustainability (forward-looking metrics).
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ ARU OCSI MSCA.CL OCSL MCX TRI NEWTL PBB
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year.
SOJA GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB
Anyone paying even the least amount of attention to the tobacco industry is cognizant of the fact that Philip Morris (PM) is putting a full-court press on getting its IQOS smokeless product to surpass, supplant and replace tobacco products like cigarettes.
SOJA PM GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA HMNY ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR NDAQ ROKU CLDT VZ WPC OHI
When sanity and reality returns, investors will flock back into the likes of Boeing, Raytheon and Lockheed Martin for safety, capital appreciation and income.
SOJA LMT GEO EPR.PRG O.PRF CTL LTC BATS 4162 OPRF SUI.PRA VZA SUI MSCA ED MO GOV SO ARCC O MAIN RMR GOVNI ARU MSCA.CL VGR ROKU CLDT VZ WPC OHI
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB
CCT remains underleveraged and reported March 31 results just below my base case projections mostly due to lower-than-expected fee income but still covered its dividend by 97%.
CCT CLA MCQ TCAP KAP PNNT MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA WGRP TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC WG HTGX NMFC HTGY OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC PNTA
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB
PFLT continues to rally since my previous article and up almost 10% since March 1, 2018. I am expecting improved dividend coverage for the reason mentioned in this article.
ARCC GBDC FDUS FSIC MAIN PNNT TCPC PFLT NMFC CGBD GLADO ARU MSCA.CL GLAD SUNS MSCA TSLX PNTA
Following continued requests, Part 1 of this article analyzes PSEC’s near-term dividend sustainability by performing three tests based on recent (and projected) quarterly results.
MSCA.CL SLRC MSCA MAIN PBB SLRA PSEC
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET